President Donald Trump announced agreement on Most Favored Nations (MFN) drug pricing deals with Eli Lilly & Company and Novo Nordisk.
President Donald Trump announced agreement on Most Favored Nations (MFN) drug pricing deals with Eli Lilly & Company and Novo Nordisk, marking the fourth and fifth major drug companies with which the administration has reached deals in recent months.
When purchased through the forthcoming TrumpRX website, which will be operational in January, the Novo Nordisk-produced type 2 diabetes and weight-loss drugs, Wegovy and Ozempic, which also treat other conditions, will be dramatically more affordable at $350 each, down from a respective $1,350 and $1,000 per month, according to a White House release.
Eli Lilly & Company’s type 2 diabetes and weight loss drugs, Zepbound and Orforglipron, will see reductions from $1,068 a month to an average of $346 a month when patients buy them through the TrumpRx website.
